Triptorelin doesn't prevent chemo-induced ovarian failure

May 27, 2016

(HealthDay)—Triptorelin plus norethisterone (GnRHa) does not prevent chemotherapy-induced premature ovarian failure (POF) in young patients with lymphoma, according to a study published online May 23 in the Journal of Clinical Oncology.

Isabelle Demeestere, M.D., Ph.D., from the Université Libre de Bruxelles in Belgium, and colleagues reported the final analysis of a cohort of 129 patients with lymphoma who were randomized to receive GnRHa or norethisterone alone (control) during chemotherapy. After two, three, four, and five to seven years of follow-up, ovarian function and fertility were reported. Overall, 67 patients (26.21 ± 0.64 years of age) had available data after a median follow-up of 5.33 and 5.58 years in the GnRHa and control groups, respectively.

The researchers found that the risk of POF was significantly increased according to age (P = 0.047), the conditioning regimen for transplant (P = 0.002), and the cumulative dose of cyclophosphamide >5 g/m² (P = 0.019); the risk was not increased with co-administration of GnRHa during chemotherapy (odds ratio, 0.702; P = 0.651). Both groups had similar ovarian reserve, evaluated using anti-Müllerian hormone and follicle-stimulating hormone levels. In the GnRHa and control groups, 53 and 43 percent, respectively, achieved pregnancy (P = 0.467).

"These results reopen the debate about the drug's benefit in that it should not be recommended as standard for fertility preservation in patients with ," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; triptorelin was provided by the Ipsen Pharmaceutical Group.

Explore further: Triptorelin doesn't avert early ovarian failure in lymphoma

More information: Abstract
Full Text

Related Stories

Triptorelin doesn't avert early ovarian failure in lymphoma

November 7, 2012
(HealthDay)—Treatment of lymphoma patients with the gonadotropin-releasing hormone agonist (GnRHa) triptorelin plus norethisterone does not reduce the rate of chemotherapy-induced premature ovarian failure (POF), according ...

Long-term outcomes of preventing premature menopause during chemotherapy

December 22, 2015
Compared with receiving chemotherapy alone, women with breast cancer who also received the hormonal drug triptorelin to achieve ovarian suppression had a higher long-term probability of ovarian function recovery, without ...

High doses of triptorelin needed for ovarian suppression in SLE

May 4, 2015
(HealthDay)—For female patients with childhood-onset systemic lupus erythematosus (SLE) who require treatment with cyclophosphamide, sustained complete ovarian suppression is achieved in 90 percent of the patients with ...

Comparing chemical and surgical castration for prostate cancer

December 23, 2015
Surgical castration to remove the testicles (orchiectomy) of men with metastatic prostate cancer was associated with lower risks for adverse effects compared with men who underwent medical castration with gonadotropin-releasing ...

Intraperitoneal chemo offers lasting benefit in ovarian cancer

March 27, 2015
(HealthDay)—Intraperitoneal (IP) chemotherapy offers lasting benefit for patients with advanced ovarian cancer, according to a study published online March 23 in the Journal of Clinical Oncology.

Therapy appears to reduce rate of chemotherapy-induced early menopause for women with breast cancer

July 19, 2011
Temporarily suppressing ovarian function with use of the hormone analogue triptorelin reduced the occurrence of early menopause induced by chemotherapy among women with breast cancer, according to a study in the July 20 issue ...

Recommended for you

Research team discovers drug compound that stops cancer cells from spreading

June 22, 2018
Fighting cancer means killing cancer cells. However, oncologists know that it's also important to halt the movement of cancer cells before they spread throughout the body. New research, published today in the journal Nature ...

Dying cancer cells make remaining glioblastoma cells more aggressive and therapy-resistant

June 21, 2018
A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.

Existing treatment could be used for common 'untreatable' form of lung cancer

June 21, 2018
A cancer treatment already approved for use in certain types of cancer has been found to block cell growth in a common form of lung cancer for which there is currently no specific treatment available.

Novel therapy makes oxidative stress deadly to cancer

June 21, 2018
Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.

Higher body fat linked to lower breast cancer risk in younger women

June 21, 2018
While obesity has been shown to increase breast cancer risk in postmenopausal women, a large-scale study co-led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher found the opposite is true ...

Researchers uncover new target to stop cancer growth

June 21, 2018
Researchers at the University of Wisconsin-Madison have discovered that a protein called Munc13-4 helps cancer cells secrete large numbers of exosomes—tiny, membrane-bound packages containing proteins and RNAs that stimulate ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.